Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Prasinezumab · RO7046015, PRX002

Monoclonal antibody · developed by Hoffmann-La Roche

Phase 3 Most advanced trial
3 Registered trials

What is Prasinezumab?

Prasinezumab (also known as RO7046015, PRX002, RG-7935) is administered by intravenous infusion in clinical trials in Parkinson's disease.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as
RO7046015, PRX002, RG-7935
Drug type
Monoclonal antibody
Therapy area
Neurology
Developer
Hoffmann-La Roche
In trials of
PRTA
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 3
UNII
P3Z0Z3P1ZI

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT07174310 Phase 3 Parkinson's Disease Recruiting PRTA
NCT03100149 Phase 2 Parkinson's Disease Active not recruiting PRTA
NCT02157714 Phase 1 Parkinson's Disease Completed PRTA

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Parkinson's Disease

Sources

Updated Oct 25, 2026.

Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.